United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 14,108 shares of United Therapeutics stock in a transaction on Thursday, January 10th. The stock was sold at an average price of $113.51, for a total transaction of $1,601,399.08. Following the completion of the transaction, the chief executive officer now owns 7,194 shares in the company, valued at approximately $816,590.94. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
UTHR stock opened at $114.86 on Friday. United Therapeutics Co. has a 12-month low of $100.06 and a 12-month high of $143.73. The stock has a market capitalization of $4.95 billion, a price-to-earnings ratio of 10.55, a PEG ratio of 42.74 and a beta of 1.12. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.05 and a current ratio of 4.32.
United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, October 31st. The biotechnology company reported $2.42 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.23 by ($0.81). United Therapeutics had a net margin of 31.73% and a return on equity of 25.24%. The firm had revenue of $412.70 million during the quarter, compared to analysts’ expectations of $378.22 million. During the same quarter in the previous year, the firm posted $4.69 EPS. United Therapeutics’s revenue was down 7.4% compared to the same quarter last year. As a group, equities analysts predict that United Therapeutics Co. will post 14.28 EPS for the current year.
A number of equities analysts recently commented on the stock. BidaskClub upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Friday, January 4th. ValuEngine cut shares of United Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd. Oppenheimer set a $160.00 price objective on shares of United Therapeutics and gave the company a “buy” rating in a research report on Tuesday, November 20th. Credit Suisse Group boosted their price objective on shares of United Therapeutics from $103.00 to $105.00 and gave the company a “sell” rating in a research report on Monday, November 19th. Finally, Cowen set a $106.00 price objective on shares of United Therapeutics and gave the company a “hold” rating in a research report on Thursday, November 15th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $134.00.
Several hedge funds have recently added to or reduced their stakes in UTHR. Globeflex Capital L P bought a new stake in shares of United Therapeutics during the 3rd quarter valued at about $192,000. Advisor Partners LLC bought a new stake in shares of United Therapeutics during the 3rd quarter valued at about $201,000. Unison Advisors LLC bought a new stake in shares of United Therapeutics during the 3rd quarter valued at about $224,000. Campbell & CO Investment Adviser LLC bought a new stake in shares of United Therapeutics during the 3rd quarter valued at about $229,000. Finally, Balasa Dinverno & Foltz LLC bought a new stake in shares of United Therapeutics during the 3rd quarter valued at about $260,000. Hedge funds and other institutional investors own 97.13% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Martine A. Rothblatt Sells 14,108 Shares of United Therapeutics Co. (UTHR) Stock” was originally published by Zolmax and is the property of of Zolmax. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://zolmax.com/investing/martine-a-rothblatt-sells-14108-shares-of-united-therapeutics-co-uthr-stock/2820086.html.
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Featured Story: What is Depreciation?
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.